How should haloperidol (Haldol) 5 mg/mL be prepared and administered?

Haloperidol 5mg/mL Preparation and Administration

Haloperidol 5mg/mL is supplied as a ready-to-use sterile solution for intramuscular injection only—no preparation is required, and intramuscular administration is the preferred parenteral route over intravenous due to safety concerns. 1

Preparation

• No dilution or reconstitution needed: The 5mg/mL formulation comes ready to administer directly from the vial 1
• Storage: Keep at 20-25°C (68-77°F), protect from light, do not freeze 1
• Handling: Use aseptic technique when drawing up the medication
• Vial presentation: Available as 1mL single-dose vials containing 5mg haloperidol (as lactate) 1

Administration Routes and Dosing

Intramuscular (IM) - Preferred Parenteral Route

For acute agitation/delirium, start with 0.5-1mg IM, with PRN dosing of 0.5-1mg every 1 hour as needed 2. The intramuscular route is explicitly preferred over intravenous administration in emergency settings due to superior safety profile 3.

• Standard adult dose: 0.5-1mg IM stat, repeat 0.5-1mg IM every 1 hour PRN 2
• Older/frail patients: Use lower doses (0.25-0.5mg) and titrate gradually 2
• Scheduled dosing: If needed, give every 8-12 hours 2
• Higher doses: Up to 5mg IM has been studied for severe agitation 4

Subcutaneous (SC)

• Same dosing as IM: 0.5-1mg SC stat, 0.5-1mg SC every 1 hour PRN 2
• Useful alternative when IM access is difficult

Intravenous (IV) - Use With Extreme Caution

IV haloperidol carries an FDA non-black box warning due to deaths associated with high doses and IV administration—reserve only for profoundly hypotensive patients failing multiple IM injections and volume resuscitation 3.

If IV administration is deemed absolutely necessary:

• Bolus: 0.1-0.3mL (0.5-1.5mg) of 1:1000 solution in 10mL normal saline over several minutes 5
• Continuous infusion: Add 1mg (1mL) to 250mL D5W = 4mcg/mL concentration; infuse at 1-4mcg/min (15-60 drops/min), maximum 10mcg/min 5
• Requires continuous ECG monitoring due to QTc prolongation risk (mean 7ms prolongation) 3

Oral (PO)

• When transitioning from parenteral: 0.5-1mg PO, same frequency as parenteral dosing 2

Critical Safety Considerations

Cardiac Monitoring

• QTc prolongation: Haloperidol causes mean 7ms QTc prolongation 3
• Risk factors requiring caution: Electrolyte abnormalities, concurrent QT-prolonging medications, cardiac disease 3
• ECG monitoring mandatory for IV administration 2

Contraindications and Warnings

• Avoid in: Parkinson's disease, dementia with Lewy bodies (high extrapyramidal symptom risk) 2
• Extrapyramidal symptoms (EPS): Acute dystonia, akathisia, drug-induced Parkinsonism can occur, especially after first doses 3
• Laryngeal dystonia: Rare but life-threatening—presents as choking, difficulty breathing, stridor 3

Dose-Response and Adverse Events

Recent evidence shows higher doses (>2mg) increase adverse event risk without improving efficacy 6, 7. A 2023 study demonstrated low-dose haloperidol (≤0.5mg) had similar efficacy to higher doses with better safety outcomes 6.

Adverse event rates by formulation 8:

• Oral: 2% adverse events
• IM: 15% adverse events (OR 7.63 vs oral)
• IV: 19% adverse events (OR 10.17 vs oral)

Combination Therapy

• Often combined with benzodiazepines (lorazepam 2mg) for severe agitation 4
• Compatibility: Stable with morphine for 9-10 days, but unstable with scopolamine (≤1 day stability) 9
• Polypharmacy caution: Adding benzodiazepines/diphenhydramine increases complexity without clear benefit 7

Common Pitfalls to Avoid

1. Using IV route routinely: Reserve for life-threatening situations only—IM is safer and equally effective 3
2. Overdosing elderly patients: Always start at 0.25-0.5mg in older/frail patients 2, 6
3. Ignoring EPS risk: Have diphenhydramine available for acute dystonic reactions
4. Inadequate monitoring: Check baseline ECG if using IV route or in high-risk cardiac patients
5. Using in Parkinson's/Lewy body dementia: Absolute contraindication due to severe EPS risk 2

Practical Algorithm

For acute agitation in adults:

1. Start 0.5-1mg IM (0.25-0.5mg if elderly/frail)
2. Reassess every 15-30 minutes
3. Repeat 0.5-1mg IM every 1 hour PRN (maximum frequency per guidelines)
4. If inadequate response after 2-3 doses, consider adding lorazepam 1-2mg IM
5. Transition to scheduled dosing (every 8-12 hours) if ongoing need
6. Monitor for EPS, QTc changes, oversedation